Major Dynavax Investor Deep Track (14.82% Stake) Fights ISS as Heplisav Market Share Drops to 43%

Deep Track Capital Comments on ISS Recommendation

Strongly Disagrees with Recommendation and Believes ISS Ignored Key Issues in Its Incomplete Analysis ISS Has Chosen Not to Hold the Board Accountable for Its Underperformance in Recent Years, Heplisav’s Waning Market Share Growth and Poor Corporate Governance Urges Shareholders to Vote FOR Deep Track’s Four Highly Qualified Director Nominees GREENWICH, Conn.–(BUSINESS WIRE)–Deep Track Capital, LP, (together with its affiliates, “Deep Track” o…

Major Dynavax Investor Deep Track (14.82% Stake) Fights ISS as Heplisav Market Share Drops to 43%

Deep Track challenges ISS analysis, citing Heplisav's declining market share and governance concerns. See why the 14.82% stakeholder urges shareholders to vote for new directors.